News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Rahul Gosain: Osimertinib now FDA approved after LAURA Phase III study
Photo from Rahul Gosain/LinkedIn
Sep 28, 2024, 07:02

Rahul Gosain: Osimertinib now FDA approved after LAURA Phase III study

Rahul Gosain shared the following on LinkedIn:

“Osimertinib now FDA approved based off LAURA: Ph III, Indefinite Osimertinib after ChemoXRT in Stage III mEGFR NSCLC: New SoC.

Key results:

  • Increase PFS with Osi, 39.1mos vs 5.6mos (HR 0.16)
  • 2yr PFS: 65% vs 13%
  • Improved CNS PFS
  • ≥Gr 3 AEs: 35% vs 12%.”

Source: Rahul Gosain/LinkedIn

Drs. Rohit Gosain and Rahul Gosain (aka Oncology Brothers),  are medical oncologists/hematologists. Through their social media platforms like X/Twitter, they actively engage with their audience. With their own YouTube channel and podcast, they provide accessible resources for cancer patients and their families.

Additionally, their participation in live conferences ensures that cancer patients receive the best care closer to home, reflecting their commitment to advancing oncology and improving patient outcomes through education and outreach.

adverse events cancer CNS PFS FDA approval LAURA trial mEGFR NSCLC new standard of care OncoDaily Oncology osimertinib phase III progression-free survival Rahul Gosain
Special Coverage
Blog
Jan 20, 2025, 04:32
Bevacizumab and carboplatin-pemetrexed chemotherapy with/out atezolizumab for advanced pleural mesothelioma
Blog
Jan 20, 2025, 04:29
Katsuaki Maehara: Lung EGFR mutations catalog
Opinion
Jan 20, 2025, 04:25
Elisabetta Bonzano: The identification and validation of patient-specific vulnerabilities
Blog
Jan 20, 2025, 04:21
Robin Zon: Behind every diagnosis, test, approval/ disapproval and outcome is a patient and their family
Insight
Jan 20, 2025, 04:14
Laura Bukavina discusses a paper on BCG treatment for patients with urothelial carcinoma of the prostatic urethra
Insight
Jan 20, 2025, 04:00
FDA approved datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Career
Jan 20, 2025, 03:10
Lawrence “Larry” Deist Appointed to Board of Directors at Rally Foundation for Childhood Cancer Research
Blog
Jan 20, 2025, 02:54
Drew Moghanaki: A new medical oncology position at the VA Medical Center in Long Beach
Science
Jan 20, 2025, 02:44
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical HL
Science
Jan 20, 2025, 02:16
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
Blog
Jan 20, 2025, 02:14
Akriti Jain: Grateful to present at Cleveland Clinic ASH review
Career
Jan 19, 2025, 23:12
Kimryn Rathmell Steps Down as NCI Director, Concluding a Pivotal Leadership Era